ENTITY
BeiGene

BeiGene (6160 HK)

309
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
23 Oct 2023 17:39

Quiddity HK Connect SOUTHBOUND Flows (To 20 Oct 23): Meituan, SMIC, Great Wall!

SOUTHBOUND flows last week were still mildly positive making it 13 weeks in a row. Great Wall Motors is finally a large net buy.

Logo
452 Views
Share
17 Oct 2023 09:18

Innovent Biologics Placement (1801.HK) - There Is No Such Thing as a Free Lunch

Innovent's recent strong share price performance reflects the market's enthusiasm for weight loss drugs. Compared with weight loss pipeline of...

Logo
811 Views
Share
bullishJapan Post Bank
15 Oct 2023 05:50

Index Rebalance & ETF Flow Recap: HSCEI, HSTECH, TOPIX FFW, SSE50, AS51, ChiNext, Kenedix, Liontown

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
748 Views
Share
10 Oct 2023 06:11

HSCEI Index Rebalance Preview: One Change; Capping Impact Increases

China Unicom IN, Zhongsheng Group OUT likely. Passive trackers will need to trade over 2x ADV on both stocks. Meituan, Alibaba, Tencent capped...

Logo
701 Views
Share
08 Oct 2023 10:15

A-H Premium Weekly (Oct 6th): CMB, Postal Savings, Conch Cement, Beigene, Sinopec

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Cm Bank, Postal Savings, Conch Cement, Beigene, Sinopec Corp.

Logo
426 Views
Share
x